Trial Summary
What is the purpose of this trial?This trial is testing a new MRI scan method for men with newly diagnosed prostate cancer. The scan combines detailed imaging and water movement analysis to detect cancer. The goal is to see if this method is as effective as the standard MRI but simpler and cheaper.
Eligibility Criteria
This trial is for treatment-naive patients with clinically significant prostate cancer (Gleason score > 3+4, cancer core length > 4mm) needing an MRI before treatment or biopsy. Excluded are those with pacemakers, conditions preventing MR imaging at 3T, under age 18, unable to use an endorectal coil, prior androgen therapy or prostate treatments, over 400 pounds weight, unable to consent or recent biopsy.Inclusion Criteria
I am expected to have a biopsy guided by fusion imaging at MD Anderson.
I have intermediate risk prostate cancer and have not received any treatment yet.
I am expected to have surgery at MD Anderson and will be followed up clinically.
+1 more
Exclusion Criteria
Patients allergic to gadolinium
Patients unable to tolerate an endorectal coil
Patients whose weight exceeds 400 pounds
+6 more
Participant Groups
The study tests a simplified MRI method called biparametric MRI (RSI + T2WI), which could be faster and cheaper than the standard multiparametric MRI by omitting certain sequences like DCE imaging. It aims to see if this simpler method can still effectively detect and stage prostate cancer.
1Treatment groups
Experimental Treatment
Group I: MRI techniqueExperimental Treatment1 Intervention
restriction spectrum imaging (RSI) can detect prostate cancer better than a standard-of-care MRI.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
M D Anderson Cancer CenterHouston, TX
Loading ...
Who Is Running the Clinical Trial?
M.D. Anderson Cancer CenterLead Sponsor